Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.
Identifieur interne : 002081 ( Ncbi/Merge ); précédent : 002080; suivant : 002082Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.
Auteurs : Fariborz Rahimi [Iran] ; Angela C. Roberts [États-Unis] ; Mandar Jog [Canada]Source :
- Clinical neurology and neurosurgery [ 1872-6968 ] ; 2016.
English descriptors
- KwdEn :
- Aged, Female, Gait Disorders, Neurologic (drug therapy), Gait Disorders, Neurologic (etiology), Humans, Indans (administration & dosage), Indans (pharmacology), Male, Middle Aged, Monoamine Oxidase Inhibitors (administration & dosage), Monoamine Oxidase Inhibitors (pharmacology), Outcome Assessment (Health Care), Parkinson Disease (complications), Parkinson Disease (drug therapy), Pilot Projects.
- MESH :
- chemical , administration & dosage : Indans, Monoamine Oxidase Inhibitors.
- complications : Parkinson Disease.
- drug therapy : Gait Disorders, Neurologic, Parkinson Disease.
- etiology : Gait Disorders, Neurologic.
- chemical , pharmacology : Indans, Monoamine Oxidase Inhibitors.
- Aged, Female, Humans, Male, Middle Aged, Outcome Assessment (Health Care), Pilot Projects.
Abstract
Freezing of gait (FoG) is a challenging clinical symptom in Parkinson's disease with variable improvements in FoG with rasagiline. In this prospective, uncontrolled, pre-/post- treatment pilot study, we explore the clinical variables that contribute to this variability and those that predict improvement.
DOI: 10.1016/j.clineuro.2016.08.025
PubMed: 27618783
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000126
- to stream PubMed, to step Curation: 000126
- to stream PubMed, to step Checkpoint: 000126
Links to Exploration step
pubmed:27618783Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.</title><author><name sortKey="Rahimi, Fariborz" sort="Rahimi, Fariborz" uniqKey="Rahimi F" first="Fariborz" last="Rahimi">Fariborz Rahimi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Electrical Engineering, Bonab University, Bonab, Iran. Electronic address: frahimi@bonabu.ac.ir.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Electrical Engineering, Bonab University, Bonab</wicri:regionArea><wicri:noRegion>Bonab</wicri:noRegion></affiliation></author><author><name sortKey="Roberts, Angela C" sort="Roberts, Angela C" uniqKey="Roberts A" first="Angela C" last="Roberts">Angela C. Roberts</name><affiliation wicri:level="2"><nlm:affiliation>Northwestern University, Roxelyn and Richard Pepper Department of Communication Sciences and Disorders, 2240 Campus Drive, Evanston, Illinois, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Northwestern University, Roxelyn and Richard Pepper Department of Communication Sciences and Disorders, 2240 Campus Drive, Evanston, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Jog, Mandar" sort="Jog, Mandar" uniqKey="Jog M" first="Mandar" last="Jog">Mandar Jog</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurosciences, London Health Sciences Centre, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, London Health Sciences Centre, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27618783</idno><idno type="pmid">27618783</idno><idno type="doi">10.1016/j.clineuro.2016.08.025</idno><idno type="wicri:Area/PubMed/Corpus">000126</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000126</idno><idno type="wicri:Area/PubMed/Curation">000126</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000126</idno><idno type="wicri:Area/PubMed/Checkpoint">000126</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000126</idno><idno type="wicri:Area/Ncbi/Merge">002081</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.</title><author><name sortKey="Rahimi, Fariborz" sort="Rahimi, Fariborz" uniqKey="Rahimi F" first="Fariborz" last="Rahimi">Fariborz Rahimi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Electrical Engineering, Bonab University, Bonab, Iran. Electronic address: frahimi@bonabu.ac.ir.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Electrical Engineering, Bonab University, Bonab</wicri:regionArea><wicri:noRegion>Bonab</wicri:noRegion></affiliation></author><author><name sortKey="Roberts, Angela C" sort="Roberts, Angela C" uniqKey="Roberts A" first="Angela C" last="Roberts">Angela C. Roberts</name><affiliation wicri:level="2"><nlm:affiliation>Northwestern University, Roxelyn and Richard Pepper Department of Communication Sciences and Disorders, 2240 Campus Drive, Evanston, Illinois, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Northwestern University, Roxelyn and Richard Pepper Department of Communication Sciences and Disorders, 2240 Campus Drive, Evanston, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Jog, Mandar" sort="Jog, Mandar" uniqKey="Jog M" first="Mandar" last="Jog">Mandar Jog</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurosciences, London Health Sciences Centre, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, London Health Sciences Centre, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical neurology and neurosurgery</title><idno type="eISSN">1872-6968</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Female</term><term>Gait Disorders, Neurologic (drug therapy)</term><term>Gait Disorders, Neurologic (etiology)</term><term>Humans</term><term>Indans (administration & dosage)</term><term>Indans (pharmacology)</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase Inhibitors (administration & dosage)</term><term>Monoamine Oxidase Inhibitors (pharmacology)</term><term>Outcome Assessment (Health Care)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Pilot Projects</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Indans</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Indans</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Outcome Assessment (Health Care)</term><term>Pilot Projects</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Freezing of gait (FoG) is a challenging clinical symptom in Parkinson's disease with variable improvements in FoG with rasagiline. In this prospective, uncontrolled, pre-/post- treatment pilot study, we explore the clinical variables that contribute to this variability and those that predict improvement.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27618783</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>13</Day></DateCreated><DateCompleted><Year>2017</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-6968</ISSN><JournalIssue CitedMedium="Internet"><Volume>150</Volume><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Clinical neurology and neurosurgery</Title><ISOAbbreviation>Clin Neurol Neurosurg</ISOAbbreviation></Journal><ArticleTitle>Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.</ArticleTitle><Pagination><MedlinePgn>117-124</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0303-8467(16)30309-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clineuro.2016.08.025</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Freezing of gait (FoG) is a challenging clinical symptom in Parkinson's disease with variable improvements in FoG with rasagiline. In this prospective, uncontrolled, pre-/post- treatment pilot study, we explore the clinical variables that contribute to this variability and those that predict improvement.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Frequency and duration of FoG, along with other standardized scales, were evaluated in 18 optimally medicated PD participants with intractable FoG, prior to and after completion of a 90-day course of 1mg daily rasagiline. Gait tasks were video-recorded and analyzed by two independent reviewers. After evaluating the simple main effect, hierarchical cluster analysis was used to identify subgroups for treatment responsiveness. Bidirectional elimination stepwise regression analysis was conducted to identify which clinical variables predicted reduction in frequency of FoG events post-treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no overall pre-/post- treatment improvements, a result driven by a heterogeneous response to treatment. Three subgroups were identified: improved (n=6) with a 136% and 162% reduction in FoG count and duration; worsened (n=5) with 154% and 141% increase in FoG count and duration; and no change (n=3). The final predictive model had good explanatory power (adjusted-R(2)=0.9898, p<0.01), explaining 99% of the variance between the improved and worsened groups. In this model, lower UPDRS gait scores, higher LEDD dose, lower anxiety scores, lower FOG-Q scores, and higher UPDRS scores for lower extremity rigidity and rise from chair, predicted FoG-related rasagiline benefit.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Using both objective and subjective measures for FoG, the current pilot study identified a set of clinical variables that may elucidate the heterogeneous FoG-responsiveness following rasagiline treatment and aid in predicting improvement.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rahimi</LastName><ForeName>Fariborz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Electrical Engineering, Bonab University, Bonab, Iran. Electronic address: frahimi@bonabu.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Angela C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Northwestern University, Roxelyn and Richard Pepper Department of Communication Sciences and Disorders, 2240 Campus Drive, Evanston, Illinois, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jog</LastName><ForeName>Mandar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, London Health Sciences Centre, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Neurol Neurosurg</MedlineTA><NlmUniqueID>7502039</NlmUniqueID><ISSNLinking>0303-8467</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment (Health Care)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Freezing of gait</Keyword><Keyword MajorTopicYN="Y">Parkinson’s disease</Keyword><Keyword MajorTopicYN="Y">Rasagaline</Keyword><Keyword MajorTopicYN="Y">Treatment</Keyword><Keyword MajorTopicYN="Y">Variability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>08</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27618783</ArticleId><ArticleId IdType="pii">S0303-8467(16)30309-2</ArticleId><ArticleId IdType="doi">10.1016/j.clineuro.2016.08.025</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>Iran</li><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><country name="Iran"><noRegion><name sortKey="Rahimi, Fariborz" sort="Rahimi, Fariborz" uniqKey="Rahimi F" first="Fariborz" last="Rahimi">Fariborz Rahimi</name></noRegion></country><country name="États-Unis"><region name="Illinois"><name sortKey="Roberts, Angela C" sort="Roberts, Angela C" uniqKey="Roberts A" first="Angela C" last="Roberts">Angela C. Roberts</name></region></country><country name="Canada"><noRegion><name sortKey="Jog, Mandar" sort="Jog, Mandar" uniqKey="Jog M" first="Mandar" last="Jog">Mandar Jog</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002081 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002081 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27618783
|texte= Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27618783" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |